Abstract
Vitiligo is a common autoimmune disease of the skin resulting from the destruction of epidermal melanocytes by cytotoxic CD8+ T cells. It presents with multiple white macules and patches, which can significantly affect patients’ self-esteem and quality of life. Vitiligo is estimated to affect about 1–2% of the population, regardless of gender and ethnicity (more than 3 million individuals in the United States). Existing treatments are non-targeted, time-consuming, and offer moderate efficacy. With the exception of monobenzone cream (monobenzyl ether of hydroquinone), which is used to permanently depigment unaffected skin in patients with widespread vitiligo, there are currently no Food and Drug Administration (FDA)–approved medical treatments, and so management of vitiligo is primarily through the use of off-label therapies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
